Phase I/II – Other

632 trials 274 recruiting

Filter these 632 trials by condition, country, sponsor and more.

Open in Search →

Intervertebral Disc Regeneration by Autologous Stem Cell Transplantation Ended

2024-514475-17-00 degenerative disc disease 2022-11-15
A Study to Evaluate the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen-Exposed Patients with Relapsed/Refractory Multi… Ended

2023-505865-94-00 Relapsed/Refractory Multiple Myeloma 2022-10-26
A FIRST-IN-HUMAN (FIH) STUDY OF IDRX-42 IN PARTICIPANTS WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS (GIST) Ended

2024-514930-19-00 metastatic and/or unresectable gastrointestinal stromal 2022-10-07
Multicentric randomized phase I / II study to evaluate efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α True Human… Ended

2024-517024-20-00 Metastatic colorectal cancer patients 2022-09-27
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA) Ended

2023-508536-64-00 Metastatic Prostate Cancer 2022-05-17
Genetic vaccine for the treatment of microsatellite unstable solid tumors Ended

2024-514723-42-00 Locally advanced unresectable or metastatic, microsatel 2022-05-05
A Study to Evaluate NTLA-2002 in adults with Hereditary Angioedema (HAE) Ended

2024-512317-40-00 Hereditary Angioedema 2022-04-13
A study to assess the Safety, Tolerability, Pharmacokinetics and Anti tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lun… Ended

2024-512127-36-00 Non-Small Cell Lung Cancer 2022-03-31
Belantamab Mafodotin in combination with Daratumumab, Lenalidomide and Dexamethasone for the treatment of patients with newly diagnosed mul… Ended

2024-515634-32-00 newly diagnosed multiple myeloma 2022-03-31
A Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide in Patients with … Ended

2023-507993-42-00 Relapsed or Refractory Diffuse Large B-Cell Lymphoma ( 2022-03-17
Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children aged ≥ 1 to < 7 Years with Neurofibromatosis Type 1… Ended

2023-506357-38-00 Neurofibromatosis Type 1 (NF1) Related Plexiform Neurof 2022-02-17
A phase 2 study to investigate the effectiveness of combination immunotherapy followed by chemoradiation of the tumor in patients with bladd… Ended

2024-512211-41-00 Urothelial carcinoma of the bladder and bladder cancer 2022-01-26
OASIS II - A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib-Venetoclax plus CD20 Ab in patients with untreated ma… Ended

2024-512634-15-00 Patients with untreated mantle cell lymphoma 2022-01-05
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with Polatuzumab Ved… Ended

2023-506986-74-00 B-cell non-Hodgkin lymphoma (NHL) 2021-12-27
An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult … Ended

2024-512903-38-00 Relapsed or refractory B cell acute lymphoblastic leuka 2021-12-01
A study to evaluate the safety and efficacy of CR6086 in combination with balstilimab (AGEN2034), in patients with pretreated mismatch-repai… Ended

2024-515446-16-00 Pretreated mismatch-repair-proficient and microsatellit 2021-11-23
An open label, multicenter, phase I/II study of belantamab mafodotin in combination with Kd for the treatment of relapsed myeloma patients, … Ended

2024-517006-28-00 Multiple myeloma 2021-11-23
Trial of different schemes of PM14 alone and in combination with radiotherapy in soft tissue sarcomas and other solid tumors Ended

2024-519893-38-00 Soft tissue sarcomas and other solid tumors 2021-11-23
An open-label phase 1b/2 study assessing the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic… Ended

2024-514905-79-00 Metastatic pancreatic ductal adenocarcinoma 2021-09-17
Phase 1 / 2 Study Evaluating MCLA-129 in Advanced NSCLC Ended

2024-514461-19-00 Solid Tumors 2021-09-09
A clinical study of pembrolizumab with other study treatments in people with refractory lung cancer (MK-3475-B98) Ended

2023-507687-38-00 Participants with extensive-stage small cell lung cance 2021-08-23
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants Wit… Ended

2023-503624-83-00 Anaemia associated with myelofibrosis 2021-08-16
A Phase 1b/2 Study of BMS-986158 Monotherapy and Combination with either Ruxolitinib or Fedratinib in Intermediate or High Risk Myelofibrosi… Ended

2023-509635-89-00 DIPSS-Intermediate or High Risk Myelofibrosis 2021-06-01
Isatuximab in combination with belantamab mafodotin and dexamethasone in RRMM. Ended

2024-514989-40-00 Cancer 2021-05-17